Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio Inc (NY: ANVS )

9.280 +4.010 (+76.09%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,734,309
Open 5.330
Bid (Size) 9.550 (4)
Ask (Size) 9.600 (1)
Prev. Close 5.270
Today's Range 4.530 - 12.51
52wk Range 4.530 - 22.49
Shares Outstanding 11,171,480
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
ANVS stock closed up more than 75% today after Annovis announced encouraging clinical trial results for its Parkinson's drug, buntanetap. 
Via InvestorPlace
What's Going With Annovis Bio Shares Tuesday?
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap. 
Via Benzinga

Performance

YTD
-50.98%
-50.98%
1 Month
+36.27%
+36.27%
3 Month
-16.99%
-16.99%
6 Month
-50.98%
-50.98%
1 Year
-34.25%
-34.25%

More News

Read More
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease
Via Investor Brand Network
Peering Into Annovis Bio's Recent Short Interest
Via Benzinga
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Annovis Announces New Publication in a Peer-Reviewed Journal
From Annovis Bio Inc.
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024
Via InvestorPlace
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
From Annovis Bio Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.